HIGH-RESOLUTION RESPIROMETRY AS A TOOL TO ASSESS SKELETAL MUSCLE MITOCHONDRIAL STATE IN PATIENTS WITH HUNTINGTON'S DISEASE

<u>Svetlana Kopishinskaia</u> ^{1,2,3,4}, Pavel Pchelin ^{5,6}, Mariya Korotysh ⁴, Sergey Svetozarsky ⁷, Tatiana Kovaleva ⁶, Sergey Nikitin ⁸, Irina Mukhina ^{5,6}

¹ Kirov Medical University, Kirov, Russia

² International Center for Education and Research in Neuropsychiatry, Samara State Medical University, Samara, Russia

³ First Genetics Co., Skolkovo Innovation Center, Moscow, Russia

⁴ LTD "Genome", Nizhny Novgorod, Russia

⁵ Lobachevsky State University, Nizhny Novgorod, Russia

⁶ Privolzhsky Research Medical University, Nizhny Novgorod, Russia

⁷ Volga District Medical Center, Nizhny Novgorod, Russia

⁸ Medical Center "Practical Neurology", Moscow, Russia

EHDN 2021

Experiment design

Table 1. Summary of clinical details



High-Resolution Respirometry, mtMP (HRR, Oroboros Oxygraph-2k, Austria)

* - according to Doerrier et al (2018) High-Resolution FluoRespirometry and OXPHOS Protocols for Human Cells, Permeabilized Fibers from Small Biopsies of Muscle, and Isolated Mitochondria // Mitochondrial Bioenergetics. Methods in Molecular Biology, vol 1782.

Method: HRR



LEAK - uncoupled respiration during the non-phosphorylating resting state;

OXPHOS - coupled respiration during oxidative phosphorylation;

ETC - electron transfer system capacity during noncoupled respiration;

ROX - residual oxygen consumption;

mtMP – mitochondrial membrane potential

С

Fig.1. A – graph of skeletal muscle respiration (oxygen concentration, blue line; respiration rate, red line), B – graph of mtMP (mtMP, black line; mtMP dynamics, green line), C – Oroboros O2k-Respirometer (Oroboros Instruments, Austria)

Results



Fig. 3. *Coupled* respiration during oxidative phosphorylation (OXPHOS) is decreased in premanifest HD patients both for complex I (CI) and complexes I+II (CI+CII)

		OXPHOS _{CI} (pmol O ₂ s ⁻¹ ml ⁻¹ mg ⁻¹)	OXPHOS _{CII} (pmol O ₂ s ⁻¹ ml ⁻¹ mg ⁻¹)	OXPHOS _{CI+CII} (pmol O ₂ s ⁻¹ ml ⁻¹ mg ⁻¹)
Control	PM Control	26,5541 ± 1,9626	18,2448 ± 7,4554	44,7989 ± 7,4959
	M Control	$27,9434 \pm 6,4966$	$12,9254 \pm 5,9286$	$40,\!8687\pm12,\!0068$
HD	Premanifest (PM)	20,7371 ± 2,6575*	13,6076 ± 5,2996	34,3447 ± 4,4222*
	Manifest (M)	27,8112 ± 4,1924**	$18,2433 \pm 5,9322$	46,0546±5,5781**

Data are means \pm SD, n=7-8. * = significant difference with matched control, ** = significant difference with premanifest 4

Results



Fig. 4. No significant differences between controls and HD patients were observed in *uncoupled* respiration during the non-phosphorylating resting state (LEAK_n), and in *noncoupled* respiration (ETC_{CI+CII})

		LEAK _n (pmol O ₂ s ⁻¹ ml ⁻¹ mg ⁻¹)	ETC _{CI+CII} (pmol O ₂ s ⁻¹ ml ⁻¹ mg ⁻¹)	ET-C _{CII} (pmol O ₂ s ⁻¹ ml ⁻¹ mg ⁻¹)
Control	PM Control	$7,2270 \pm 3,3743$	58,6285 ± 8,6164	27,3540 ± 6,1773
	M Control	10,9205 ± 3,0547	55,4783 ± 13,5851	23,0443 ± 4,5433
HD	Premanifest (PM)	7,9054 ± 2,1263	48,4246 ± 8,2777	23,6001 ± 4,4871
	Manifest (M)	11,9351 ± 4,2412	$58,3268 \pm 7,4686$	$29,9741 \pm 6,7018$

HRR can be used as a promising tool to assess mitochondrial state in skeletal muscles from patients with HD.

Our results demonstrate alterations in coupled mitochondrial respiration of skeletal muscle observed in the premanifest stage of Huntington's Disease (HD). Analyzing male and female cohorts separately, it was shown that the observed decrease in respiration rates of premanifest patients is sex-independent.

The dynamics of mtMP was on the same level in HD patients and matched controls. The tendency to less pronounced changes in mtMP were observed in premanifest and manifest patients in comparison to matched controls.

According to the data, the function of the mitochondrial respiratory chain and ATP production can be limiting factors for the aerobic metabolism of skeletal muscles in the early stages of HD.